common-pharma-interest common-risks-of-working-as-a-healthcare-professional 
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
pharmaphorum
NOVEMBER 25, 2021
Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketing practices, including the digitisation of events. Before COVID, pharma events were mainly face-to-face. The changing events model.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Viseven
OCTOBER 26, 2022
Over the past couple of years, there have been many pharma company challenges. Unfortunately, this is the reality we are living in because of pharma supply chain challenges. Need for Qualified Professionals. The lack of qualified professionals is one of the biggest problems in pharmaceutical industry. Invest in software.
pharmaphorum
JANUARY 27, 2023
Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceutical company – our recent interview provided some interesting insights into the changing landscape of the industry.
The People's Pharmacy
MAY 8, 2023
ProPublica performs “investigative journalism in the public interest.” Probably not…and for good reason. Pilots perform a long list of comprehensive preflight checks to make sure the plane is in perfect running condition before takeoff. States require that elevators are regularly inspected. ” How Good Is Your Medicine?
Pharma Marketing Network
JUNE 8, 2020
Don (PMN): Hi good morning everyone, welcome to the pharma marketing podcast. I come to the pharma space from being a medical operator of clinics for the last 15 to 20 years where we took care of patients with specific disease conditions that were often overlooked. Bob and Mark thanks for joining us today. Mark (83Bar): Yea thank you.
pharmaphorum
OCTOBER 10, 2022
Any delay in diagnosis or treatment can severely impact the options available to patients and healthcare professionals. As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness.
Expert insights. Personalized for you.
98 
Let's personalize your content